Fagron Compounding Services's Complete FDA Record

FDA action counts

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Fagron Compounding Services has 5 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event.

Enforcement history

On 2026-04-15, Argus HQ recorded a FDA recall for Fagron Compounding Services, rated "high" severity in Argus HQ's classification: Fagron Compounding Services — Class II recall: Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP,… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-15, Argus HQ recorded a FDA recall for Fagron Compounding Services, rated "high" severity in Argus HQ's classification: Fagron Compounding Services — Class II recall: Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, F… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-15, Argus HQ recorded a FDA recall for Fagron Compounding Services, rated "high" severity in Argus HQ's classification: Fagron Compounding Services — Class II recall: norepinephrine Bitartrate, 32mg per 250mL 0.9% Sodium Chloride Injection USP, Fa… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-15, Argus HQ recorded a FDA recall for Fagron Compounding Services, rated "high" severity in Argus HQ's classification: Fagron Compounding Services — Class II recall: Vancomycin HCL, 1 gram added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagr… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-15, Argus HQ recorded a FDA recall for Fagron Compounding Services, rated "high" severity in Argus HQ's classification: Fagron Compounding Services — Class II recall: norepinephrine Bitartrate,16mg per 250mL 0.9% Sodium Chloride Injection USP, Fag… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. In total, Fagron Compounding Services has 5 FDA events on file with Argus HQ across the sources Argus HQ currently tracks (FDA Warning Letters, recalls, drug/biologic approvals, and Form 483 inspection observations).

Frequently asked questions

How many FDA actions does Argus HQ track for Fagron Compounding Services?

6 total: 0 warning letters, 5 recalls, 0 approval records, and 1 Form 483 inspection citation.

What is the most recent FDA action on file for Fagron Compounding Services?

April 15, 2026. Argus HQ ingests new FDA enforcement records daily.

Has Fagron Compounding Services had product recalls?

Yes, 5 recalls on file. See the full history below for each one.

Is this FDA enforcement data for Fagron Compounding Services official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Related enforcement actions

• Fagron Compounding Services — Class II recall: norepinephrine Bitartrate, 32mg per 250mL 0.9% Sodium Chloride Injection USP, Fa… →
• Fagron Compounding Services — Class II recall: Vancomycin HCL, 1 gram added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagr… →
• Fagron Compounding Services — Class II recall: norepinephrine Bitartrate,16mg per 250mL 0.9% Sodium Chloride Injection USP, Fag… →
• Fagron Compounding Services — Class II recall: Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP,… →
• Fagron Compounding Services — Class II recall: Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, F… →
• Fagron Compounding Services -- FDA 483: 3 observations (2025-08-08) →

Compare with

• Fagron Compounding Services vs Medline Industries, LP
• Fagron Compounding Services vs ARROW INTERNATIONAL, LLC
• Fagron Compounding Services vs Stryker Sustainability Solutions
• Fagron Compounding Services vs Guardian Drug Co. Inc.
• Fagron Compounding Services vs B BRAUN MEDICAL INC